Literature DB >> 2675751

Effect of lomefloxacin on theophylline pharmacokinetics.

D E Nix1, A Norman, J J Schentag.   

Abstract

A study involving 25 health male volunteers was conducted to evaluate the effect of lomefloxacin on the pharmacokinetics of theophylline. The mean age was 22.4 +/- 3.0 years, and the mean weight was 77.3 +/- 7.7 kg. A single 6-mg/kg aminophylline dose was given intravenously on study days 1 and 15. The subjects received a 400-mg lomefloxacin dose (four 100-mg capsules) on study days 9 through 15. No treatment was given on study days 2 through 8. Thirteen blood samples were collected within 24 h after each aminophylline dose. Theophylline concentrations in serum were measured by enzyme immunoassay (EMIT). The mean aminophylline dose was 437 +/- 36 mg, equivalent to 344 mg of theophylline. Multiple doses of lomefloxacin had no effect on the area under the concentration-time curve from 0 h to infinity, maximal concentration, or clearance of theophylline from serum. There was a slight increase in the theophylline half-life from 6.72 +/- 1.63 to 7.02 +/- 1.37 h after lomefloxacin dosing (P = 0.04); however, the change was clinically insignificant. No change in theophylline dose is required when lomefloxacin therapy is instituted in a patient receiving theophylline.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2675751      PMCID: PMC176053          DOI: 10.1128/AAC.33.7.1006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  A clinically significant interaction between ciprofloxacin and theophylline.

Authors:  A H Thomson; G D Thomson; M Hepburn; B Whiting
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Effect of enoxacin and 4-oxo-enoxacin on antipyrine disposition in the rat.

Authors:  D J Edwards; N M Waite; C K Svensson
Journal:  Drug Metab Dispos       Date:  1988 Jul-Aug       Impact factor: 3.922

3.  Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum.

Authors:  J Schwartz; L Jauregui; J Lettieri; K Bachmann
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

4.  Effect of norfloxacin on theophylline pharmacokinetics at steady state.

Authors:  S K Bowles; Z Popovski; M J Rybak; H B Beckman; D J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

5.  Effect of ofloxacin on the pharmacokinetics of a single intravenous theophylline dose.

Authors:  W A Al-Turk; O M Shaheen; S Othman; R M Khalaf; A S Awidi
Journal:  Ther Drug Monit       Date:  1988       Impact factor: 3.681

6.  In vitro activity of lomefloxacin (SC-47111; NY-198), a difluoroquinolone 3-carboxylic acid, compared with those of other quinolones.

Authors:  N X Chin; A Novelli; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

7.  Enoxacin--a potent inhibitor of theophylline metabolism.

Authors:  J Beckmann; W Elsässer; U Gundert-Remy; R Hertrampf
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Ciprofloxacin increases serum levels of theophylline.

Authors:  S Raoof; C Wollschlager; F A Khan
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

9.  Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green.

Authors:  D E Nix; J M DeVito; M A Whitbread; J J Schentag
Journal:  J Antimicrob Chemother       Date:  1987-02       Impact factor: 5.790

10.  Evaluation of the effect of norfloxacin on the pharmacokinetics of theophylline.

Authors:  G Ho; M G Tierney; R E Dales
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

View more
  13 in total

Review 1.  Pharmacokinetic interactions between theophylline and other medication (Part II).

Authors:  R A Upton
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

2.  Influence of lomefloxacin on the pharmacokinetics of theophylline.

Authors:  M LeBel; F Vallée; M St-Laurent
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 3.  Lomefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A N Wadworth; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

4.  Safety of fleroxacin coadministered with theophylline to young and elderly volunteers.

Authors:  M Parent; M St-Laurent; M LeBel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

5.  Lack of interaction between lomefloxacin and caffeine in normal volunteers.

Authors:  D P Healy; J R Schoenle; J Stotka; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

6.  Absence of effect of rufloxacin on theophylline pharmacokinetics in steady state.

Authors:  M Kinzig-Schippers; U Fuhr; M Cesana; C Müller; A H Staib; S Rietbrock; F Sörgel
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 7.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

9.  Steady-state pharmacokinetics and sputum penetration of lomefloxacin in patients with chronic obstructive pulmonary disease and acute respiratory tract infections.

Authors:  J M Kovarik; A I Hoepelman; J M Smit; P A Sips; M Rozenberg-Arska; J H Glerum; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 10.  Lomefloxacin clinical pharmacokinetics.

Authors:  C D Freeman; D P Nicolau; P P Belliveau; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1993-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.